Inhibition of PKC by Oral Administration of Ruboxistaurin Is Well Tolerated and Ameliorates Diabetes-Induced Retinal Hemodynamic Abnormalities in Patients | Zendy

Lloyd Paul Aiello | Zendy; Allen C. Clermont | Zendy; Vineet M. Arora | Zendy; Matthew D. Davis | Zendy; Matthew J. Sheetz | Zendy; Sven-Eric Bursell | Zendy

Open Access

Inhibition of PKC by Oral Administration of Ruboxistaurin Is Well Tolerated and Ameliorates Diabetes-Induced Retinal Hemodynamic Abnormalities in Patients

Author(s) -

Lloyd Paul Aiello,

Allen C. Clermont,

Vineet M. Arora,

Matthew D. Davis,

Matthew J. Sheetz,

Sven-Eric Bursell

Publication year - 2005

Publication title -

investigative ophthalmology and visual science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.935

H-Index - 218

eISSN - 1552-5783

pISSN - 0146-0404

DOI - 10.1167/iovs.05-0757

Subject(s) - medicine , placebo , diabetes mellitus , adverse effect , diabetic retinopathy , randomized controlled trial , clinical endpoint , type 2 diabetes , population , oral administration , anesthesia , endocrinology , environmental health , pathology , alternative medicine

To assess ocular and systemic safety and pharmacodynamic effects of the oral PKC beta selective inhibitor ruboxistaurin (RBX; LY333531) mesylate in patients with diabetes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research